BACKGROUND AND OBJECTIVES: Increased serum hepcidin has been reported in patients receiving chronic hemodialysis, and hypothesized to contribute to the alterations of iron metabolism of end-stage renal disease. However, no quantitative assessment is available to date; the clinical determinants are still under definition; and the role of genetic factors, namely HFE mutations, has not yet been evaluated. The aim of this study was to quantitatively assess serum hepcidin-25 in hemodialysis patients versus controls, and analyze the relationship between hepcidin, iron indices, HFE genotype, and erythropoietic parameters. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Sixty-five hemodialysis patients and 57 healthy controls were considered. Hepcidin-25 was evaluated by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, HFE genotype by restriction analysis. RESULTS: Serum hepcidin-25 was higher in hemodialysis patients compared with controls. In patients, hepcidin-25 correlated positively with ferritin and C reactive protein, and negatively with serum iron after adjustment for confounders. Hepcidin/ferritin ratio was lower in patients with (n = 25) than in those without (n = 40) HFE mutations. At multivariate analysis, hepcidin-25 was independently associated with ferritin and HFE status. In a subgroup of 22 "stable" patients, i.e., with Hb levels on target, normal CRP levels, and absence of complications for at least 1 yr, hepcidin-25 was negatively correlated with Hb levels independently of confounders. CONCLUSIONS: Serum hepcidin-25 is increased in hemodialysis patients, regulated by iron stores and inflammation, and relatively reduced in subjects carrying frequent HFE mutations. Hepcidin-25 may contribute to the pathogenesis of anemia by decreasing iron availability.
BACKGROUND AND OBJECTIVES: Increased serum hepcidin has been reported in patients receiving chronic hemodialysis, and hypothesized to contribute to the alterations of iron metabolism of end-stage renal disease. However, no quantitative assessment is available to date; the clinical determinants are still under definition; and the role of genetic factors, namely HFE mutations, has not yet been evaluated. The aim of this study was to quantitatively assess serum hepcidin-25 in hemodialysis patients versus controls, and analyze the relationship between hepcidin, iron indices, HFE genotype, and erythropoietic parameters. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Sixty-five hemodialysis patients and 57 healthy controls were considered. Hepcidin-25 was evaluated by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, HFE genotype by restriction analysis. RESULTS: Serum hepcidin-25 was higher in hemodialysis patients compared with controls. In patients, hepcidin-25 correlated positively with ferritin and C reactive protein, and negatively with serum iron after adjustment for confounders. Hepcidin/ferritin ratio was lower in patients with (n = 25) than in those without (n = 40) HFE mutations. At multivariate analysis, hepcidin-25 was independently associated with ferritin and HFE status. In a subgroup of 22 "stable" patients, i.e., with Hb levels on target, normal CRP levels, and absence of complications for at least 1 yr, hepcidin-25 was negatively correlated with Hb levels independently of confounders. CONCLUSIONS: Serum hepcidin-25 is increased in hemodialysis patients, regulated by iron stores and inflammation, and relatively reduced in subjects carrying frequent HFE mutations. Hepcidin-25 may contribute to the pathogenesis of anemia by decreasing iron availability.
Authors: A Scaccabarozzi; P Arosio; G Weiss; L Valenti; P Dongiovanni; A L Fracanzani; M Mattioli; S Levi; G Fiorelli; S Fargion Journal: Br J Haematol Date: 2000-09 Impact factor: 6.998
Authors: Francesco Locatelli; Ronald L Pisoni; Christian Combe; Juergen Bommer; Vittorio E Andreucci; Luis Piera; Roger Greenwood; Harold I Feldman; Friedrich K Port; Philip J Held Journal: Nephrol Dial Transplant Date: 2004-01 Impact factor: 5.992
Authors: Geoffrey S Teehan; Dany Bahdouch; Robin Ruthazer; Vaidyanathapuram S Balakrishnan; David R Snydman; Bertrand L Jaber Journal: Clin Infect Dis Date: 2004-04-01 Impact factor: 9.079
Authors: Lillian A Rocha; Daniela V Barreto; Fellype C Barreto; Cristiane B Dias; Rosa Moysés; Maria Regina R Silva; Luiz A R Moura; Sérgio A Draibe; Vanda Jorgetti; Aluízio B Carvalho; Maria Eugênia F Canziani Journal: Clin J Am Soc Nephrol Date: 2008-10-08 Impact factor: 8.237
Authors: Kamyar Kalantar-Zadeh; Charles J McAllister; Robert S Lehn; Enwu Liu; Joel D Kopple Journal: Am J Kidney Dis Date: 2004-04 Impact factor: 8.860
Authors: Domenico Girelli; Paola Trombini; Fabiana Busti; Natascia Campostrini; Marco Sandri; Sara Pelucchi; Mark Westerman; Tomas Ganz; Elizabeta Nemeth; Alberto Piperno; Clara Camaschella Journal: Haematologica Date: 2010-12-20 Impact factor: 9.941